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Abstract 
Biologics mainly monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) as new therapeutics 
are becoming increasingly important biotherapeutics. This review is intended to provide an overall 
comparison between small molecules (SMs) and biologics or large molecules (LMs) concerning drug 
metabolism and pharmacokinetic (DMPK) or associated with absorption, distribution, metabolism and 
elimination (ADME) testing from pharmaceutical industry drug discovery and development points of view, 
which will help design and conduct relevant ADME testing for biologics such as mAbs and ADCs. Recent 
advancements in the ADME for testing biologics and related bioanalytical methods are discussed with an 
emphasis on ADC drug development as an example to understand its complexity and challenges from 
extensive in vitro characterization to in vivo animal PK studies. General non-clinical safety evaluations of 
biologics in particular for ADC drugs are outlined including drug-drug interaction (DDI) and 
metabolite/catabolite assessments. Regulatory guidance on the ADME testing and safety evaluations 
including immunogenicity as well as bioanalytical considerations are addressed for LMs. In addition, the 
preclinical and human PK data of two marked ADC drugs (ADCETRIS, SGN-35 and KADCYLA, T-DM1) as 
examples are briefly discussed with regard to PK considerations and PK/PD perspectives. 
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1. Introduction 
Biologics or large molecules (LMs) primarily monoclonal antibodies (mAbs) and antibody-drug conjugate 
(ADC) currently represent main stream therapeutics and continue to grow in number of new approvals and 
targets recently [1-4]. A majority of these biotherapeutics are mAbs or mAb-derived proteins, which are 
subject to transformation mechanisms such as deamidation, oxidation, and isomerization [1-4]. These 
processes usually result in relatively small structural changes in the parent drugs. Such small structural 
changes may be difficult for a conventional immunoassay to differentiate, but they can still affect biological 
activity, PK and immunogenicity of a therapeutic protein [5]. Whereas ADCs are an emerging class of 
biotherapeutics that combines the target specificity of an antibody with the potent small-molecule drugs or 
cytotoxins, which can selectively deliver a potent cytotoxic drug to tumor cells via tumor-specific and/or 
over-expressed antigens with more favorable therapeutic window [1,6]. This new type of antibody-drug 
conjugate or antibody-linker-drug currently shows its great promising therapeutic options, which led to the 
recent FDA approvals of ADCETRIS (brentuximab vedotin, SGN-35) and KADCYLA (ado-trastuzumab 
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emtansine, T-DM1) for the treatment of Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphomas 
(ALCL), and HER2-positive metastatic breast cancer, respectively, as well as a rich clinical pipeline of 
potential new cancer therapies [7]. 
Throughout several decades of advancements and evolutions, ADMET profiling of small molecule (SM) 
has becomes a standardized paradigm in drug discovery and development in terms of in vitro screening, in 
vivo animal studies, LC-MS/MS based bioanalysis as well as regulatory considerations including DDI and 
drug metabolite safety testing etc. However, ADME testing of LMs lags behind that of SMs due to the 
complex nature of the biological molecules and also lack of appropriate tools to study drug exposure, 
biotransformation and target engagement in the vascular and tissue spaces [2]. ADME of LMs or biologics 
are still based on the lessons learned from the SMs and the tools that have applied to SM drugs [5]. In 
general, there is a similar high level PK/PD relation concept between the SMs and LMs, although they have 
different ADME mechanisms and underlying ADMET determinants at different stages [5]. Characterizing the 
absorption, distribution, metabolism, and excretion of these LM drugs (mAbs and ADCs) in preclinical 
animal models can better predict their efficacy and tolerability in clinic. Accordingly, it is necessary to 
understand general characteristics and the difference between SMs and LMs (e.g., antibody and ADC) in 
order to apply relevant approaches for ADME testing and safety evaluation of LMs as reviewed in a number 
of recent publications [2,3,5,8-11]. In a previous review, what ADME tests should be conducted for small 
molecule drugs for preclinical studies was highlighted  [12]. This review will provide an overall comparison 
between SM and LM properties with a particular focus on ADC’s characteristics to gain a better 
understanding of in vitro and in vivo ADME testing as well as toxicity evaluations. The in-depth information 
of ADME will also be valuable for the designing of novel mAb constructs and next generation of ADCs with 
desirable PK profile and safety window. 
2. General differences between SMs and LMs (mAb and ADC) in ADME testing 
Table 1 summarizes general differences between SMs and LMs with an overall comparison of mAb and 
ADC. As highlighted in Table 1, due to the nature of various characteristics between SMs and LMs, the focus 
on ADME studies of LMs is thus different from SMs in particular for drug metabolite safety testing and DDI 
evaluations. In these aspects, in vitro models and in vivo studies and related bioanalysis including 
transporter studies and safety evaluation and high-throughput screening approaches for SMs have well 
been established across pharmaceutical industry [12-20]. Typical in vitro ADME tests for SMs are metabolic 
stability by liver microsmoes or/and hepatocytes and passive permeability on cell-line models based on 
Caco-2 or MDCK assays, which are commonly utilized to predict in vivo clearance and absorption or 
bioavailability as well as potential drug-drug interaction (DDI) evaluations and metabolism pathway studies. 
In particular, a common consensus has been reached on drug metabolite testing across various species 
from in vitro models to in vivo studies following regulatory guidance, which clearly suggests critical criteria 
for decision-tree making in assessing key drug metabolite safety in human  [21,22]. Similarly, cytochrome 
P450 (CYP) enzymes based DDI as well as transporter-mediated DDI of SMs are also defined and guided on 
the basis of many years industrious practice of drug discovery and development [23]. On the contrary, 
ADME testing of biologics (mAbs and ADCs) can be rather diverse as highlighted in Table 1 and Figure 1. 
Biodistribution of mAbs and ADCs are usually similar [24], but both have much lower Vd than that of a 
typical SM drug as the structure of mAbs or ADCs is dominated by the antibody backbone with initial 
distribution limited to the vascular space or plasma, not organ tissues. While the drug metabolism of mAbs 
is more complex due to receptor binding target-mediated drug disposition (TMDD), FcRn binding and 
lysosomal degradation, tissue protease, immune response antibody mediated metabolism etc in addition to 
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other metabolic or metabolic-like biotransformation such modifications as deamidation, oxidation, 
isomerization, disulfide bond reduction or shuffling and proteolytic or glycolytic hydrolysis (ref. therein) 
[11]. The metabolism /catabolism of ADCs can be more complicated than mAbs due to a cytotoxic drug 
linked to the antibody via a linker. Typically, the circulating unconjugated drug after the ADC administration 
has metabolic properties of small-molecule compounds. Hence, drug metabolite and DDI should be 
concerned for ADC drugs, but maybe not for mAbs wherein the DDI risk is presumably low or not as 
prominent as small molecules. Once small-molecule drugs released from the ADCs, they may be 
metabolized by CYP enzymes and thus subject to potential DDI from CYP enzyme inhibitors or inducers due 
to payload/small molecule component [9]. Furthermore, one or more active small-molecule drugs may be 
released from an ADC in vivo by additional catabolism mechanism. Accordingly, both unconjugated small-
molecule drug and released catabolites small molecules may be considered for metabolite safety and DDI 
potential evaluations for ADCs. This is considered to be a major differentiation of ADCs from mAbs 
regarding ADME testing as the degraded small molecules of mAbs are often amino acids, small peptides or 
small carbohydrates that are readily eliminated by renal excretion or return to the nutrient pool without 
biological effects or safety consideration [2]. However, it should be noted that examples of therapeutic 
protein (TP) and small-molecule drug (D) interactions in clinical studies were observed although the 
changes in exposures (AUC, Cmax) have not been as remarkable as with small-molecule drugs, and the 
types of study designs used to assess TP and D interactions were thereby outlined in CDER’s special subject 
on therapeutic protein–drug interactions and implications for drug development [25]. 
On the other hand, for LMs at early stage, more extensive in vitro characterizations are required as an 
example of screening cascade depicted in Figure 1. These typical studies include antibody primary structure 
by chemical sequencing (Edman degradation) as well as peptide mapping by means of ESI-MS and MALDI-
MS  [26-28]; higher order structure by RP-HPLC–ESI–MS, Ellman’s assay CD, FTIR, hydrogen deuterium 
exchange (HDX)-MS and X-ray [28,29]; post-translational modifications (PTM) and charge variants by MS-
ion-exchange chromatography (IEC), hydrophobic interaction chromatography (HIC), capillary 
electrophoresis (CE) and isoelectric focusing (IEF) [30]; glycan profile and variants and size heterogeneity by 
HPLC-fluorescence, size-exclusion chromatography (SEC), native gel, capillary electrophoresis, RP-HPLC-MS 
and native intact MS [31], as well as solubility measurement by ultrafiltration or PEG-induced precipitation 
methods [32,33]. Moreover, the immunogenicity should be evaluated for both antibody and ADCs [34,35], 
but unnecessary for SMs. Unlike the antibody, additional in vitro studies of ADC include drug antibody ratio 
(DAR) characterizations, conjugate site analysis, linker stability and toxin evaluations as highlighted in 
Figure 1 may be required. Furthermore, absorption needs to be understood as well if LMs are targeting for 
an SC administration. 
Despite distinct characteristics and differences of in vitro testing between antibody and ADCs and SMs 
as shown in Table 1 and Figure 1, similar principle of in vivo PK studies including mass balance and 
elimination as well as safety evaluations for SMs are generally applicable to both antibody and ADCs. 
However, different bioanalytical methods have to be applied for antibody and ADCs, which will be 
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Table 1. Characteristic comparison of small molecules (SMs) and large molecules (LMs)*  




 SMs Biologics or LMs 
  mAbs  ADC 
MW ~ 200-500 ～150 KDa  (typically) ～150 KDa  (typically) 






properties (e.g. tertiary structure, 
stability, PTM) 
Antibody + toxin 
ADME tools 
Available/ extensive ADME 
understanding 
Understanding of ADME still 
evolving 
Understanding of ADME still evolving 
Dosing route Oral often possible 
Usually parenterally (IV, SC, and 
IM), Intravitreal injection 
Usually parenterally (IV, SC, and IM) 
Dose interval Daily (typically) Intermittent dosing Intermittent dosing 
Half-life ( t1/2) Short (typically several to 24 hrs) Long (typically days or weeks) 
Long but slightly shorter than antibody 
alone 
Distribution (Vd ) 
High Vd, distribution to 
organs/tissues 
Potential substrate of transporters 
Lower  Vd , usually limited to 
plasma and/ or extracellular 
fluids 
Lower  Vd , mainly target dependent 
Metabolism 
pathway 
Mainly by CYP enzymes and phase 
II enzymes, metabolized to non-
active and active metabolites 
Catabolism 
Degraded to peptides or amino 
acids 




Toxin and released drug catabolites 
(may be concerned) 
Excretion Mainly biliary and renal excretion Mostly recycled by body Both 
Clearance  (CL) 
Mostly linear PK; non-linearity 
mainly due to saturation of 
metabolic pathways 
Slow clearance 
Lower  clearance, but slightly higher 
clearance than antibody 
Potency and 
selectivity 
Generally less selective High selectivity (affinity/ potency) High selectivity (affinity/ potency) 
PK analytes Drug and metabolites Antibody and ADA 
ADC or conjugated drug, total antibody, 
and unconjugated toxin/catabolites, 
ATA 
PK bioanalysis LC-MS/MS methods 
Mostly ELISA (total antibody), 
Recently with increased LC-
MS/MS applications 
Hybrid of ELISA (total antibody, ADC), 
high resolution LC-MS (DAR) and highly 
selective LC-/MS/MS (un-conjugated 
toxin/catabolites) 
PD Short acting Long acting Long acting 
PK/PD 
PK usually not driven by PD due to 
dominance of non-target mediated 
binding 
PK and PD mechanistically 
connected (TMDD) 
PK and PD mechanistically connected 
(TMDD) 
DDI  
Many examples and PK and/or PD 
related (by CYP enzymes or 
transporters) 
Sparse examples and mostly PD 
related 
Sparse examples and mostly PD related 
Toxin or released toxin/catabolites 
(should be concerned) 
hERG Yes No No 
Immunogenicity No Yes Yes 




Can be more toxic than antibody due to 
toxin 
Formulation Complex and diverse Simple formulation Simple formulation 
API/Production 
Process  




No generics, biosimilar or 
comparability 
Both + conjugation (mixtures of ADCs 
with different DAR 
No generics, biosimilar or comparability 
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Figure 1. Typical ADME/Tox studies for SM and antibody and ADC 
 
2.1. ADME testing of mAbs 
Fundamental ADME characteristics and PK behaviors of biologics including therapeutic proteins and 
mAbs have extensively been reviewed recently [2,11,25,36-39]. Currently, there is lack of validated in vitro 
ADME models for mAbs. In addition to extensive characterization of antibody as depicted in Figure 1, the 
major ADME testing of mAbs relies on in vivo studies such as PK and safety evaluations on relevant animal 
species. It should be noted that the selected species for in vivo PK and toxicity evaluations should 
preferably have cross-reactivity with human. Another important aspect to consider is immunogenicity for 
ADME testing of mAbs as well as ADCs, which is a key risk in biologic drug development, because 
therapeutic biotechnology-driven proteins must be as similar as possible in primary, secondary, and tertiary 
structures to its human homologues in order to avoid immunogenicity [2,40]. In general, the 
immunogenicity, specifically formation of anti-drug antibody (ADA), is one of the major complicating issues 
in nonclinical and clinical programs for therapeutic proteins, which is a regulatory requirement as part of 
the safety assessment of biotherapeutic submission [34,38,41]. The ADA production due to the continuous 
administration of mAbs may affect the PK and/or the PD of mAbs after they are administrated to patients 
[40]. When an immunogenic reaction mediated by ADAs takes place, it can increase blood clearance and 
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hampering its clinical application in some instances. Although factors that affect ADA are complex and the 
relationship of bioanalytical measures, for example, incidence and magnitude of ADA responses to clinical 
efficacy and safety are uncertain, the ADA incidence and magnitude should always be assessed relative to 
capacity of ADAs to neutralize the relevant biological activity of the therapeutic mAb, in addition to impact 
on drug levels and clinical measures of efficacy and safety [42]. In principle, it would be acceptable for the 
biologic product to be less immunogenic than the reference product, provided that this did not modify the 
efficacy of the product or increase the incidence or severity of adverse reactions, although the magnitude 
of ADA acceptance is not defined by regulators [42]. One should also bear in mind that the bioanalytical 
methods used to monitor immunogenicity are subject to various biases when interpreting ADA data and 
assessing immunogenicity. In practice, a comparison of single dosing PK and multiple dosing PK with 
monitoring ADA production over time is valuable for a better understanding of the PK/PD relation of mAbs 
as well as the part of mAb quality evaluation. To the best of our knowledge, once the ADA occurs over the 
time, the plasma concentration at certain time point can drop dramatically. Consequently, caution has to 
be taken to evaluate the PK parameters in particular calculate the half-life of mAb with different 
compartmental models to be in line with its corresponding plasma concentrations for the correct 
interpretation of PD effect or its PK/PD relationship. Additionally, mathematical modeling of ADA response 
against mAbs and its impact on mAb PK/PD has been reviewed recently [40]. 
Currently, ligand binding assay (LBA) such as enzyme-linked immunesorbent assays (ELISA) are generally 
regarded as the gold standard methods for bioanalysis of LMs with sufficient sensitivity and specificity. Of 
them, the sandwich and competition enzyme immunoassay technique are more widely utilized for 
detection and quantification of antibodies [43-45]. Typically, various coat capture reagents, conjugate 
reagents (e.g. horseradish peroxidase, HRP), peroxidase substrates (e.g. TMB, stabilized hydrogen 
peroxide/TMB) and stop solution (e.g. sulfuric acid) are employed case by case. To date, the standard ELISA 
platform has considerably been improved upon over the years, involving automation and improved 
detection methodologies, and new applications of this technique is further discussed in next bioanalysis 
section. 
2.2. ADME testing of ADCs  
ADCs are mAbs with covalently bound cytotoxic drugs via a linker, which are designed to target tumor 
antigens selectively and offer the hope of cancer treatment to decrease the off-target toxicity, thereby, 
improving the therapeutic index of the cytotoxin [41,46]. ADCs are usually comprised of 0 to 8 cytotoxic 
payloads with an average DAR of 2 to 4 per mAb, which are thus heterogeneous mixtures of conjugates. 
Given that low payloads reduce potency and high payloads negatively impact PK, the DARs can have a 
significant impact on ADC efficacy [3]. Structurally, the antibody component of the ADC accounts for the 
majority of the therapeutic agent (approximately 98 % of total ADC by molecular weight). Biologically, the 
PK of ADCs is strongly influenced by the underlying antibody backbone conferring properties such as target 
specific binding, neonatal Fc receptor (FcRn)-dependent recycling and Fc (fragment, crystallizable) effector 
functions [24]. Compared with the unconjugated antibody, ADCs can exhibit somewhat higher clearance 
due to introduction of an additional metabolic pathway (i.e. cleavage of the drug from the antibody by 
lysosomal peptide degradation). Furthermore, linker stability, DAR and site of drug conjugation can largely 
impact PK behaviors and distribution as well. Conjugation with higher DAR tends to have faster clearance 
than conjugation with lower DAR as an example of cAC10-vc MMAE ADCs with high DARs exhibiting a faster 
total antibody clearance than lower DAR ADCs [47]. Variable DARs and attachment sites by a consequence 
of current random conjugation methods result in heterogeneous ADCs with PK parameters that can vary 
substantially compared to the unconjugated antibody [24]. Hamblett et al. compared ADCs with different 
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drug loading (MMAE conjugated to the anti-CD30 mAb) and concluded that the therapeutic index was 
increased by decreasing drug loading per antibody, demonstrating that drug loading is a key design 
parameter for antibody-drug conjugates [47]. It was shown that the terminal half-lives did not directly 
correlate with drug loading. When the drug loading increased, both clearance and volume of distribution 
increased, but the exposure (AUC) of ADC decreased, reflecting the significant attribute of DAR to PK 
properties of ADC. 
The systemic stability of the antibody−drug linker is also crucial for delivery of an intact ADC to target-
expressing tumors. Linkers stable in circulation but readily processed in the target cell are necessary for 
both safety and potency of the delivered conjugate [48]. In general, linker should be stable enough in 
systemic circulation to deliver drug into tumor cells, but labile to release this fully active payload drug inside 
the tumor cells. Otherwise, the toxic drug could be released in the bloodstream, causing systemic toxicity. 
Polson et al. demonstrated that non-cleavable linker (e.g. SGN-35) is more stable than cleavable linker (e.g. 
T-DM1) [49]. The non-cleavable linker may have slower deconjugation or lower clearance than cleavable 
linker and reduced systemic toxicity of ADC in rats presumably due to the reduced release of free drug or 
other toxic metabolites into the circulation [49]. This is because the cleavable linkers may release drug by 
lysosomal proteases without the degradation of the mAb component whereas non-cleavable linkers require 
catabolism of the mAb backbones to release the drug [9 and ref. therein]. In addition, the selection of 
attachment site can affect stability of cleavable antibody-drug conjugates, as demonstrated in the design of 
systemically stable cleavable auristatin-based conjugates, offering the means to overcome inherent linker 
instability by optimal attachment site [48]. 
Interestingly, Junutula et al. [50] recently reported a site-specific conjugation method called THIOMAB 
technology enabling near-uniform, low-level conjugation of cytotoxins (DAR=2) to antitumor antibodies, 
which displayed an increased tolerability or improved therapeutic index without compromising efficacy. 
This new type of THIOMAB-drug conjugates (TDCs) with nearly homogeneous composition of conjugates 
was better tolerated than conventional ADC in monkeys, and also showed slower catabolism and 
deconjugation than ADC in rats. The THIOMAB approach provides a general strategy for improved PK and 
superior therapeutic index of any ADC generated by standard sufhydryl-directed maleimide chemistry [51]. 
Likewise, Dennler et al. more recently presented another site-specific modification of deglycosylated 
antibodies by microbial transglutaminase (MTGase) to form ADCs with a defined homogeneous DAR of 2 as 
well. This chemo-enzymatic approach was reported directly applicable to abroad variety of antibodies as it 
does not require prior genetic modifications of the antibody sequence [52]. Clearly, the designing and 
forming a homogeneous ADC can result in less complicated in vitro characterization and relatively easier in 
vivo PK bioanalysis as well as safety evaluation than a typical heterogeneous ADC. 
Apart from the DAR characterization, some in vitro ADME models and in vivo PK studies can be 
employed for ADC evaluations as illustrated in Figure 1. First ADME testing of ADCs is linker stability 
assessment both in in vitro or in vivo by LC-MS/MS method or radiolabeled ADC, respectively, in order to 
explore the impact of linker on uptake and catabolism. Secondly, free toxin was expected to undergo 
clearance mechanism studies for DDI potential including liver microsomal stability, metabolizing enzyme 
identification, CYP inhibition and induction, in vitro metabolite profiling studies [53]. Then, general in vivo 
PK studies and non-clinical safety evaluations including immunogenicity with relevant animal species are 
necessary for PCC selection. Finally, linker-containing drug catabolites should be identified and the plasma 
concentration of free drug and related catabolites should be determined by LC-MS/MS in both nonclinical 
and clinical studies for safety assessment of key metabolites or catabolites.  
 
Hong Wan  ADMET & DMPK 4(1) (2016) 1-22 
8  
ELISA was conventional method for PK/TK (toxicokinetics) study of antibody and conjugate. For instance, 
detection reagents for total and conjugated antibodies were goat antihuman IgG antibody conjugated to 
horseradish peroxidase or goat antihuman Fc conjugated to horseradish peroxidase [43]. Coat capture 
reagents were used on a case by case basis, e.g. anti-MMAE antibody (conjugated antibody), antibodies 
specific for drugs (total antibody). Biotin-DIG bridging ELISA and surface plasma resonance (SPR) techniques 
were developed for immunogenicity assessment to detect anti-therapeutic antibodies (ATAs) to the ADC, 
including ATAs towards any of the ADC molecular components such as the antibody, linker, drug or 
epitopes involving multiple ADC components. Finally, isotope-labelling method was used for the study of 
tissue distribution and mass balance [43,46,54]. Recent advances in high-throughput formats and combined 
techniques for ADC bioanalysis will be discussed in more details in the section 3. 
2.3. Safety evaluation of ADCs  
With regard to preclinical safety assessment, toxicity of ADCs is usually ADC/drug-dependent and 
antigen-independent and it can be more toxic than mAbs due to introduced cytotoxic drugs. As ADCs 
consist of a monoclonal antibody, linker and cytotoxic components, the biological activity profiles of each 
should be considered when selecting the relevant and/or appropriate species for toxicity evaluations, 
typically in two relevant species (one rodent and one non-rodent) [55]. For a particular ADC, the relevant 
toxicity species should be selected from its pharmacology and tissue-reactivity studies showing similar 
binding to human. Primary considerations for the nonclinical safety assessment of ADCs includes the 
evaluation of the entire ADC or the various individual components (i.e., antibody, linker or the cytotoxin) to 
identify the on- and off-target toxicities to enable first-in-human (FIH) studies [41]. General toxicity studies 
are recommended and following specific toxicity studies may be considered as well for overall nonclinical 
safety evaluations [25,35,41,42,56,57]: 
 Acute and chronic toxicity study on two relevant species (preferably rodent and non-rodent), or 
transgenic animals (i.e., animal modified to the human target) to attain maximum tolerated dose (MTD), 
non-observed adverse effect level (NOAEL) or the highest non-severely toxic dose (HNSTD). 
 Tissue cross-reactivity (TCR) in tissue panels from humans and toxicity species for ADC and unconjugated 
antibody 
 Genotoxicity of cytotoxin and/or linker, and ADC may be concerned 
 hERG for unconjugated drug if concentration of the unconjugated cytotoxin are detected in the serum 
during toxicity and plasma stability testing 
 Reproductive and developmental toxicity for embryofetal (EFD) toxicity assessment of ADC and 
unconjugated toxin 
 Carcinogenicity 
 Immunogenicity and anti-ADC antibody 
 CYP inhibition and induction for DDI assessment 
 Hemolysis, skin irritation and sensitization testing for biologics via injection administration. 
Another important consideration would be the concentrations of unreacted linker that remain in the 
final drug product. If the cytotoxin is a novel chemical entity, then a more detailed assessment of 
metabolism and disposition (including PK/ADME studies) may be necessary as the cytotoxic drug released 
from the ADC may be associated with loss of efficacy or increased toxicity. However, if the concentrations 
of unconjugated cytotoxin in plasma are very low, for instance, the free DM1 after administrating the 
Trastuzumab emtansine (T-DM1) was <10 ng/ml (<10 nM) at all doses [53], or maximal DM1 concentration 
did not exceed 25 ng/ml after repeated dosing of T-DM1 [58], the investigation of inhibition or induction of 
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CYP isoenzymes to assess the potential DDI should not be necessary in this case [41]. In other words, the 
risk of DDI is presumably low due to very low concentrations of cytotoxic drug released from ADCs. Despite 
this hypothesis, CYP3A4 based inhibition studies for KADCYLA and DECETRIS have been conducted, 
respectively, as the SGN-35 is metabolized with a small fraction of MMAE via oxidation by primarily CYP3A4 
and CYP3A5, and KADCYLA (T-DM1) mainly by CYP3A4 and a lesser extent by CYP3A5. Nevertheless, an in 
vitro stability of ADCs in plasma and in vivo monitoring toxin released from ADC should be conducted to 
ensure the cytotoxic drug or potential catabolites under the minimal level as such without safety issues, in 
particular for major CYP metabolism involved ADC drugs. 
On the other hand, a typical ADC consists of a distribution of several entities containing different 
numbers of cytotoxic drugs on antibody, linked at different positions, thus, the inherent heterogeneity of 
ADC complex with multiple components still remains a prominent challenge in understanding their 
properties in vivo during nonclinical development. For instance, conjugation through interchain disulfides 
can lead to these ADCs with DAR distribution ranging from 0 to 8, with each fraction potentially exhibiting a 
unique efficacy, PK property, and toxicity profile [43]. Therefore, development of more sensitive and 
specific bioanalytical methods to differentiate a single ADC and multiple ADCs would be highly valuable to 
enable quantifying ADC complex for a better understanding of attributes of each single ADC component to 
PK and PD as well as safety profiles. Although it would be ideal to monitor each individual ADC species of a 
specific DAR, this currently seems to be a technical challenge. Therefore, the most common approach is to 
monitor all ADC species, all antibody species or total antibody (TAb), and the unconjugated small molecule. 
An alternative approach is to monitor conjugated small molecules as a surrogate for ADC [9].  
Overall, a design goal of an ADC is to maximize delivery of the cell-killing agent to the tumor tissue while 
minimizing delivery to normal tissues [54]. The choices of mAbs, linker, toxin or cytotoxic drug are all 
important determinants of PK, efficacy and safety. As a result, design and conduct of relevant ADME testing 
and fronting loading PK/PD studies as well as the key safety evaluations of lead molecules as early as 
possible will facilitate PCC’s selection for their successful development.  
3. Bioanalytical methods and challenges 
In the past several decades of development of SMs, the bioanalytical strategies and approaches of SMs 
have been well established from method development, validation as well as method transfer from 
instrument to instrument and lab to lab based on LC-MS/MS according to FDA bioanaltical method 
guidance [59]. Differently from SMs, the most commonly used bioanalytical methods for LMs are ELISA 
based assays by either direct or bridging ELISA measuring the concentration of the therapeutic over time in 
plasma or serum for in vivo studies case by case. In comprehensive reviews and white papers, several 
bioanalytical methods, considerations and strategies as well as challenges have extensively been discussed 
for LMs [42,46,60-66]. This section will provide an overview on recent advancements in bioanalysis of 
mAbs, ADC, in particular with ELISA and LC-MS/MS technologies and related new approaches dealing with 
matrix interference. 
3.1 High-throughput bioanalysis 
From industry drug screening perspective, commercially automated Meso Scale Discovery (MSD) format 
and nonoscale immunoassay platform on Gyrolab offer high-throughput capabilities of ELISA bioanalysis, 
which enhances overall performance of traditional manual ELISA assay with several advantages in terms of 
sample amount, broader dynamic linearity, throughput, higher sensitivity and reproducibility [67,68]. 
Moreover, both the antibody and ADA of an antibody or ADC and ATA from PK plasma samples can be 
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quantified simultaneously. In particular, the nanoscale volume of microfludic platform on Gyros has made it 
durable to gain the PK data of antibody from one single mouse study by whole blood serial sampling with 
significantly reducing study cost and animal usage, offering comparable PK data as conventional composite 
sampling [69]. Furthermore, this microfludic approach has been applied to high-throughput quantification 
of host cell protein impurities for bioprocess development [70]. It demonstrated an improved throughput 
(5-10 times faster), broader dynamic range (100-times) and decreased sample consumption, hands on time 
and duration for assay development compared with Tecan plate-based ELISA [70]. With those automated 
instruments, ELISA based bioanalytical methods become easier transferring from preclinical to clinical 
between labs and CROs, which can considerably speed up large molecule drug discovery process and 
clinical development. Furthermore, traditional ELISA approach was transferred to an automated 
microfluidics immunoassay platform based on nanoscale streptavidin bead columns enable high-
throughput bioanalysis of a human mAb in preclinical PK samples with enhanced bioanalysis capacity [71]. 
Additionally, a high-throughput capillary electrophoresis based microfluidic device (LabChip GXII) was 
applied to obtain pharmacokinetics (PK) of a fluorescently labeled human mAb directly in single dose rat PK 
studies [72]. 
3.2 LC-MS/MS and BLA bioanalysis of mAbs 
As mentioned above, LBA-based ELISA is the commonly used gold standard method for bioanalysis of 
mAbs. Recent advances in instrumentation technology have significantly increased the sensitivity and 
versatility of LC-MS/MS, making it an alternative tool for large molecule drug development. With 
appropriate sample preparation (based on the MW and concentration of the target analyte of interest), 
immmunocapture LC-MS/MS methods can achieve levels of high sensitivity down to 0.01 to 0.1 nM closer 
to ELISA assays with a large dynamic range and orthogonal specificity that is generally unaffected by cross-
reaction issues [61]. In recent comparative studies, Peng et al. developed and validated a simple, sensitive, 
specific and precise LC–MS/MS assay for quantitation of infliximab PK in human serum by using isotope-
labeled signature peptide as the internal standard (IS), which achieved an excellent correlation with ELISA 
detection [73]. ParK et al. applied LC-MS/MS quadruple time-of-flight mass spectrometric method (QTOF) 
for the determination of trastuzumab in rat plasma with good sensitivity (LLOD 0.5 µg/ml) and results in 
consistence with ELISA assay (R2=0.9104) [74]. Zhang et al. reported a generic automated LC-MS/MS 
method for the pharmacokinetic study of a mAb in cynomolgus monkey with comparable data by the 
immunoassay data as well [75]. Li et al. developed a general LC-MS/MS method approach employing an 
uniformly heavy-isotope labeled common whole mAb IS and a common immunocapture for sample 
processing for qualification of four IgG(2) and four IgG(1) mAbs. This general LC-MS/MS method approach 
overcomes the limitations of current methods to reduce time and resources required for preclinical studies 
[76]. 
The key benefits of LC-MS/MS over ELISA based method are its high degree of specificity and its ability 
to simultaneously resolve, detect, and quantify multiple peptides in biological samples or their extracts, as 
well as even able to identify key metabolites of biologics, in-depth structural characterization and 
functional insights of therapeutic mAbs, e.g., differentiating biosimilar to originator mAbs as the case of 
trastuzumab and cetuximab, which will be valuable for biobetters and next generation antibodies design 
and optimization [77]. Highly selective LC-MS/MS made it possible for simultaneous quantification of 
several co-administered human antibodies (mAbs), mAb-A and mAb-B of IgG4 subclass in cynomolgus 
monkey serum with LLOQ around 5-25 µg/mL [78], which cannot be obtained by ELISA assay. As 
demonstrated in recent examples, Xu et al. successfully applied a multiplexed hybrid LC-MS/MS 
pharmacokinetic assay to measure two co-administrated mAbs in a clinical study without requiring 
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stringent affinity capture reagents [79]. Lebert and coworkers also demonstrated absolute and multiplexed 
LC-MS/MS method combining a strategy so-called PSAQTM (protein standard absolute quantification or 
stable isotopically-labeled full-length mAbs) as the ISs for quantification of three mAbs variants with very 
similar sequences, e.g., IgG1, IgG2 and igG4 isotypes of a lead mAb in rat serum, which can be employed for 
both preclinical and clinical studies [80]. Moreover, a versatile immunoaffinity LC-MS/MS method was 
developed to quantify total receptor activator of nuclear factor-kappaB ligand (RANKL) in the presence of 
denosumab, a humanized monoclonal antibody (mAb) specific to RANKL with an LLOQ of RANKL down to 
3.13 ng/mL for mouse plasma PK, which was not able to determine the total RANKL because the 
interference of denosumab decreased the recovery of RANKL with commercial ELISA kit [81]. Additionally, 
2D-LC (LC×LC)–MS/MS methodology with improved MS detection limit of approximately two orders of 
magnitude over direct LC–MS/MS was recommended [82], as well as other LC-MS formats and approaches 
such as capillary LC-MS gaining MS sensitivity were reviewed [66], offering new opportunities in the 
analysis of monoclonal antibodies. 
On the other hand, mass spectrometry methods (MALDI-TOF, Q-TOF, LTQ-Orbitrap) have been reported 
for metabolite identification or profiling (MetID) (e.g. deamidation of asparaginyl and glutaminyl residues), 
preclinical and clinical PK/TK studies with no cross-reaction [61]. Direct analysis of therapeutic monoclonal 
antibodies, without size reduction through enzyme digestion, is more challenging since these molecules 
may have a molecular weight up to 150 kDa, forming a large distribution of charge states during 
electrospray ionization (ESI), thus resulting in a complex mass spectrum with decreased sensitivity. To 
overcome these difficulties, the strategy consists of decreasing their size by proteolytic digestion in order to 
form 1000 to 2000 Da peptides with few charge states (between 2 and 4) which can be readily quantified in 
MRM mode on ESI-mass spectrometers. In another recent protocol, detailed mass analysis of structural 
heterogeneity in monoclonal antibodies at the intact protein level under pseudo-native conditions using 
native mass spectrometry was reported [83]. This method can be used for different applications such as the 
analysis of mixtures of mAbs, drug-antibody conjugates and the analysis of mAb PTMs, including the 
qualitative and quantitative analysis of mAb glycosylation, and it offers several advantages in terms of 
speed, sensitivity and specificity and high-throughput analysis. Overall, there is a need for general and 
reliable LC-MS assays capable of supporting the bioanalysis of a variety of human monoclonal antibody-
based therapeutics such as reported universal peptide approach to the bioanalysis of human monoclonal 
antibody protein drug candidates in animal PK/TK studies [84].  
3.3 LC-MS/MS and BLA bioanalysis of ADCs 
Due to the fact that the ADCs are complex mixtures incorporating large and small-molecule 
characteristics, this poses more unique bioanalytical challenges for ADC than mAb to measure ADCs and 
their catabolites in plasma and serum [46]. These challenges include ADC bioanalysis such as quantifying 
ADC and DAR in serum/plasma for PK studies and strategies for assessing immunogenicity. Since ADC 
species with different DAR distribution may display different potencies, the measured plasma 
concentrations may not accurately reflect the associated PD effect. As a general rule, both total antibody 
assay and conjugate antibody assay based on ELISA are needed to measure plasma concentrations over the 
time. In addition, ADC complexity may increase in in vivo due to biotransformation by catabolism or 
metabolism, leading to additional changes in DAR or dynamically changing mixtures. Therefore, a standard 
calibration curve consisting of the reference standard may not be appropriate for quantification of analytes 
in vivo. Biotransformation may result in ADC analytes in vivo that differ from those in the reference 
standard in vitro. A notable example was characterization of ADC (trastuzumab emtansine) drug 
distribution in a cynomolgus monkey PK study by HER2 extracellular domain affinity capture LC–MS, which 
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showed the ADR distribution shifts to lower values over time, e.g., DAR=2.76 at day 1, 1.86 at day 10, 0.68 
at day 28, respectively [46]. Apparently, the DAR composition of ADC in vivo can vary due to drug 
deconjugation or metabolic clearance. Therefore, it is important to assess the reference standard 
calibration curve appropriately for all PK time points to gain accurate DAR and PK data for a better 
understanding of PD effect. In this case, as suggested by the ADC working group of AAPS and Genentech 
scientists, a comparative analysis of assay performance for samples prepared with unconjugated antibody 
and samples prepared with ADC preparations with varying DAR values may be conducted [46,62]. Both 
types of QC samples should ideally produce back-calculated concentrations within the expected acceptable 
range of the assay (e.g., ±20 %). In addition, recoveries for QC samples generated using unconjugated 
antibody and ADC preparations with varying DAR values may be compared [62]. Likewise, Dere et al. 
demonstrated a comparison of serum T-DM1 concentrations obtained by using the total-trastuzumab and 
conjugated-trastuzumab ELISA assays using the T-DM1 as the reference standard, which showed an 
excellent linear regression (R2=0.995 and a slope =1.04) [60].  
Often diverse bioanalytical methods, a combination of LBA, high resolution LC-MS and high sensitive LC-
MS/MS method, are applied to measure ADC related analytes such as drug- antibody conjugate, 
unconjugated antibody and free toxin as well as metabolite/catabolites. Selecting the appropriate LC-
MS/MS method of a large molecule largely depends on its molecular features and the required assay 
sensitivity or expected concentration range in the sample matrix to be analyzed. The affinity capture LC-MS 
and affinity capture hydrophobic interaction chromatography (HIC) methods developed for ADC 
characterization provide powerful tools for understanding the fate of ADCs in vivo [85].  
3.4 Matrix interference 
Another bioanalytical challenge is matrix interference with reagents in biological samples in LBA when 
evaluating PK or ADA, e.g., circulating drug may interfere with the detection of ADA and drug target, or ADA 
may interfere with quantitation of drug levels in PK/TK bioanalysis. In addition to the most commonly used 
sample dilution method, the Emergent Technologies Action Program Committee (ETAPC) working group has 
recently discussed several emerging technologies such as the Singulex® Erenna® platform, Quanterix’s 
proprietary SiMoa™ technology (single molecule array), ANP Technologies’ NPX4000 Nanoparticles, SQI 
Diagnostic’s Ig PLEX™ and Genalyte’s Maverick™ technology, the Maverick detection system, to deal with 
matrix effect on possible false positive or negative ADA detection [86]. Moreover, Zoghbi et al. have 
developed a breakthrough novel method using precipitation and acid dissociation (PandA) to overcome 
drug interference in the ADA assay, showing significant improvement over the current approaches in 
detecting of ADA for two IGg1 and IGg4 drugs as the examples [87]. It was thus claimed that the principle of 
this novel assay could be used not only for ADA assays but also PK and biomarker (drug target) analysis in 
the presence of interference factors. 
4. Regulatory considerations 
Regulatory guidance on metabolites and DDI as well as bioanalytical considerations for SMs is well 
defined [21-23,39,59,88]. In the recent FDA guidance [89], bioanalytical consideration for biopharmaceutics 
has also been included for industry bioanalytical method validation. General guidelines on preclinical safety 
evaluations including immunotoxicity of biotechnology-derived pharmaceuticals are available [34,55,90]. 
Currently, it seems no requirement or guidance for metabolic investigation of mAbs from regulatory 
agencies probably because it is generally accepted that mAbs are unlikely to undergo significant 
biotransformation. The products of lysosomal degradation of mAbs are assumed to be small peptides, 
amino acids and small carbohydrates that are readily eliminated by renal excretion or return to the nutrient 
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pool without biological effects. However, this assumption may not be true for mAb derivatives such as 
fusion proteins and antibody–drug conjugates (ADCs) [2]. Indeed, therapeutic protein-drug interactions and 
implications for drug development have been observed in clinic [25,91]. As a consequence, DDI studies on 
biologics have been outlined in the draft guidance [23], which becomes a major concern for safety 
evaluations of biologic for investigational new drug (IND) filing. Unlike the mAbs, an additional 
consideration for ADCs is the ADME and safety evaluations of novel cytotoxic compounds since the 
cytotoxic drug or its derivatives can be regarded as the API rather than intermediate during ADC synthesis 
from regulatory compliance and CMC perspectives. For instance, the unreacted cytotoxic drug or linker 
might remain in the final ADC drug product. If the concentrations of these impurities are minimal (e.g., <0.2 
%), then independent testing of this component may not be necessary [92,93], and vice versa. According to 
recent suggestions by CDER and AAPS experts [94], free drug related impurities in clinical lot should be 
qualified relative to data from toxicology studies. Comparable drug/antibody ratios should be maintained 
between the toxicology lot and the clinical lot. Characterization of the impurity profile of drug/linker 
intermediates including structure determination of individual impurities (even likely intermediates) at levels 
>0.1 % is recommended prior to pivotal clinical trials. Again, given the examples of two approved ADC 
drugs, e.g. Adcetris and Kadcyla, ADME testing and non-clinical safety assessments of the ADC as well as the 
cytotoxic drug according to the CMC criteria are essential for IND filing.  
Regardless of the regulatory pathway, characterization, comparability, release and stability assays need 
to be appropriate for the molecule to be analyzed. Before more detailed guidelines on LM bioanalysis are 
available [89], an alternative LC-MS/MS technique is anticipated to serve as a complementary technique to 
quantify the antibody or ADC in plasma for more applications of PK determinations as well as the quality 
control of LMs. Given the fact of increasingly growing interest in biotherapeutics, development and 
validation of cutting-edge bioanalytical methods are highly desirable for novel mAbs and next generation of 
ADCs. Strong regulatory guidance and standard industry best practices for ADMET testing of LMs and 
related bioanalytical considerations are expected to assess and manage the potential risk of 
biotherapeutics. 
5. Analysis and interpretation of preclinical animal PK of ADCs and human PK prediction 
One ultimate purpose of ADMET testing is to understand the metabolism pathway of target molecule in 
various in vitro and in vivo species enable to better predict human PK. In general, the human clearance of 
SMs is more predictable combining in vitro and in vivo animal data by means of well-stirred model and 
commonly used allometric scaling etc [95-99]. The examples applying allometric scaling have been 
reviewed for predictions of clearance and volume distribution of therapeutic proteins recently [37]. 
However, it was argued recently that the utility of allometric scaling and body surface area (BSA) to 
translate dosage from animal models to human clinical trials are inappropriate for human PK prediction due 
to interspecies difference in drug metabolism clearance and absorption [100]. For mAbs exhibiting a linear 
PK without the TMDD, allometric scaling approach applying different scaling exponents is applicable for 
clearance and volume distribution predictions [101]. Alternatively, PBPK modeling is considered as more 
accurate human PK predictions for large molecules with the linear PK [102], but it requires a number of 
input parameters to enable accurate human PK predictions, which limits its applicability in drug 
development. A recent survey shows that minimal PBPK (mPBPK) model offers a more mechanistic 
approach using the major structural features of full PBPK models for mAbs in specifically analyzing mAb PK 
than found in compartment models and provides an intermediary method if a full PBPK model is not 
available [103]. Comparative evaluations of prediction approaches for projecting human PK of mAbs in early 
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drug development prior to the first-in-human (FIH) have been reviewed and decision tree in support of mAb 
human PK projection has been proposed recently [104]. For LMs with a nonlinear PK involved in the TMDD 
process, the predictability of plasma and tissue PK can be much more challenging particularly for ADCs. 
Despite this complexity, a mechanistic framework based on TMDD model was proposed to describe the PK 
of ADCs and simulate the PK of T-DM1 as the example [105]. Chen et al. [106] have utilized the PBPK 
modeling as a tool to predict MMAE-based DDI potential drug interactions of ADCs in good agreement with 
the observed data from clinical DDI data.  
In our preliminary analysis of two approved ADCs, it seems no linear regression between log(CL) and 
log(BW) cross species when performing an allometric scaling for either SGN-35 or T-DM1 based on data in 
Table 2 (further analysis is under way). This may highlights an example of an unpredictable human 
clearance (CL) from preclinical animal PK data by allometric scaling approach, or at least for these two 
marked ADC drugs examined herein, due to in different clearance mechanisms of ADCs and SMs. 
Furthermore, in view of preclinical animal PK data and human PK behaviors of Adcetris (SGN-35) and 
Kadcyla (T-D1) at two representative doses as summarized in Table 2, it appears that the half-lives of both 
ADCs in human are relatively shorter than in rodent species such as mouse and rats, but closer to monkey. 
Also, it should be pointed out that some of reported t1/2 data are not consistent with the calculated t1/2 
values resulting from a relationship of Vd and CL, i.e., (t1/2=0.693×Vd/CL), reflecting the different ways in 
calculating and reporting t1/2. Bear in mind that the application of different compartmental models can 
result in various half-lives, e.g., distribution half-life, elimination or terminal half-life, which should be 
clarified in PK calculations. Thus, it is important to ensure the reported t1/2 data in line with the decline of 
plasma concentration in order to correctly interpret dosing regimen as well as PK/PD relation as addressed 
above. Moreover, as shown in Table 2, an increased dose generally results in an increased t1/2 as a result of 
a decreased CL and slightly increased Vd in both preclinical species and human. This may be explained by 
complex clearance mechanisms of biologics by their specific interactions with cellular receptors or 
described as “TMDD” [11], in addition to possible CYP metabolism resulting from cytotoxin. More 
specifically, once bound, drugs mainly undergo endocytosis and subsequent lysosomal degradation, 
dependent on the ratio of receptor/drug concentration, i.e., as the drug level increases or the number of 
receptors diminishes, the proportion of drug internalized and metabolized decreases, contributing to a 
lower clearance and consequently longer half-lives. Furthermore, both AUC and Cmax’s increment of two 
ADCs is greater than dose proportional when dose increases in both preclinical species and human. 
However, no obvious accumulations were observed in TK analysis, which is different from small molecule 
drugs wherein drug accumulation could often occurs when the CYP metabolism enzymes could be 
saturated at higher doses by non-linear exposure especially for low clearance compounds. 
On the other hand, from PK/PD perspective, it is generally accepted that small drug molecules are 
rapidly equilibrated at steady state with the same free concentration (unbound) between plasma and 
tissues, which means that PK/PD can be assessed based on free plasma concentrations without measuring 
tissue levels. In contrast, therapeutic biologics generally with limited and variable distribution in tissues, 
and serum levels are not necessarily predictive for tissue levels. Added to that, biologics are administered 
mainly parenterally, so, ADME testing generally focus on biodistribution or the relationship between tissue 
concentration and efficacy. As mentioned above, ADCs may have a dose proportional PK of in rats probably 
due to no specific binding/no cross-reactivity, but a non-linear PK in cynomolgus monkeys due to cross-
reactivity/specific binding. This has raised a challenge in predicting human PK as well as human dose based 
on traditional approaches applied for small molecules owing to limited number of species and cross-
reactivity. In other words, how will preclinical data be translated to clinic in term of human PK and dose 
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prediction? In order to better understand the PK/PD relationship and toxicity profile of ADCs, total mAb, 
ADC or released payload might need to be measured in both plasma and tumor. In addition, conducting PD 
evaluations requires a clear understanding of the interaction of mAb/ADC with the target at early stage as 
possible, which may help PK/PD for human efficacy and dose prediction. PK/PD modeling and simulation 
(M&S) may provide an excellent tool to overcome these challenges, as it can simultaneously integrate the 
PK/PD of ADCs and their components in a quantitative manner [111,112]. Additionally, the computational 
PK/PD models can also serve as a cornerstone for the model-based drug development and preclinical-to-
clinical translation of ADCs. For instance, Shah et al. has developed a mechanistic model able to predict 
clinical response by integrating all preclinical biomeasures and PK/PD data of Brentuximab-vedotin [113]. 
Khot et al. highlighted the applications of M&S to gain distinct insights into ADC development for PK/PD 
and toxicodynamic data by integrating a diverse array of in vitro, preclinical and clinical data generated at 
different stages of ADC development [114]. 
 
Table 2. Preclinical and human PK data of ADC drugs (Adcetris and Kadcyla)* 
Drug   Mouse Rat Monkey Human 
Adcetris 
(brentuximab 
vedotin, SGN-35 ) 
Dose (mg kg
-1
) 10 — 0.5 5.0 0.3 1.0 1.2 2.7 
Cmax (µg mL
-1





) 2313 — 20 253 11 55.3 46.1 125.8 
t1/2 (days) 16.9 — 14.6 8.5 1.8 2.7 3.8 6.0 





) 4.4 — 25 20 27.7 18.5 26.0 21.5 
Vss (mL kg
-1







) 0.3 15 0.3 20 0.3 3.0 0.3 4.8 
Cmax (µg mL
-1





) — — — — 7.5 180 14.5 673 
t1/2 (days) 4.2 13.1 4.9 5.4 0.9 2.9 1.3 4.1 





) 13.0 19.2 10.1 22.1 40.4 16.5 21.1 7.1 
Vss (mL kg
-1
) 40.5 62.9 72.9 149 44.2 60.7 35.7 41.2 
*Adcetris/SGN-35 mouse PK data from ref. [47], rat and monkey PK data from ref. [107] and human PK data from ref. [108]. Kadcyla/T-
DM1 mouse and rat PK data from ref. [109], monkey PK data from ref. [110] and human PK data from ref. [58]. t1/2 (calculated) data 
obtained by the relationship between Vd and CL data (t1/2=0.693Vd/CL). 
Despite considerable differences between preclinical PK data and unpredictable human PK as well as 
complex PK/PD implication, Saber and Leighton recently reported an FDA analysis of ADCs on FIH dose 
selection [115]. Based on an FDA oncology analysis of INDs for ADCs using preclinical data (plasma stability, 
toxicities in animals, and toxicology study designs), it was concluded that ADCs can share the same small 
molecule drug concerning FIH dose selection. More specifically, selecting a FIH dose such as 1/6th the 
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HNSTD in cynomolgus monkeys or 1/10th the STD10 in rodents scaled according to BSA generally resulted 
in the acceptable balance of safety and efficient dose-escalation in FIH trial. This certainly provides an 
encouraging guideline to support the safety evaluation of ADCs and FIH dose selection for clinical 
development by similar approach as small molecule drugs in this aspect.  
6. Concluding remarks 
Biologic large molecules hold unique characteristics from small chemical entities. Overall, the principles 
of ADME testing for SMs can be applied to testing biologics such as mAbs and ADCs. However, there are 
remarkable differences between SMs and LMs in ADME assays associated with bioanalytical strategies. In 
comparison with ADME testing of SMs, there are limited in vitro models for ADME testing of LMs. Also, 
fewer species with cross-reactivity can be utilized for in vivo PK studies as well as safety evaluations for 
LMs. For initial ADC evaluation, In vitro plasma stability assay combined with monitoring the free toxin 
released from ADC in in vivo plasma can be utilized as a surrogate before conducting complicated and lab-
intensive bioanalytical method development for PK quantification. From ADME perspective, the design of 
novel linkers and the application of new conjugation technologies for uniform DAR can not only further 
improve ADC stability and consequent PK profiles as well as tolerability in systemic circulation of ADCs, but 
also make bioanalysis of ADC relatively easier.  
General ADME/PK testing and nonclinical toxicity studies should be conducted for both ADC and 
cytotoxin as appropriate, as exemplified in two approved ADC drugs (Adcetris and Kadcyla). Owing to fact 
that many elements such as antibody, free toxin, linker stability as well as product attributes can be ADC 
toxicity determinants, ADME testing and safety evaluations of ADC are much more complex with significant 
development challenges, requiring unique and customized nonclinical ADME approaches that differs from 
classical ADME studies for SMs. It appears that safety evaluation of key drug metabolite for ADC drugs may 
be considered as a minor issue as long as the released cytotoxic concentration is far below its MTD 
concentration. However, the DDI studies on mAbs or ADCs (both ADC and cytotoxic drug) are strongly 
recommended by FDA guidance because of increased use of biotherapeutics and clear evidence of protein-
drug interactions observed in clinic. Relevant tools need to be developed for early DDI assessment of mAbs 
or ADCs with small molecules and other biologics for predicting clinical risk. Additionally, it is anticipated 
that new methods are likely to be developed for a much better understanding of the immunotoxic potential 
from preclinical observations to clinic relevance. 
PK of LMs is often PD-dependent and it might have a dose proportional PK owing to no specific 
binding/no cross-reactivity or otherwise non-linear PK due to specific binding/cross-reactivity. Currently, 
the prediction of human PK and translation of preclinical PK/PD models to clinic are challenging especially 
for ADCs due to limited species with cross-reactivity as well as complex TMDD and CYP enzymes based 
metabolism pathways. In addition, it requires simultaneous quantitative understanding about the PK/PD 
properties of three different molecular species, i.e., the monoclonal antibody, the drug, and the conjugate 
in both serum and tissues. Further understanding PK prediction models of LMs and refining PK/PD based on 
M&S are needed for human PK and efficacy predictions and dose optimization. 
Currently, LBA-based ELISA is primarily preferred method for bioanalysis of mAbs on available high-
throughput formats. Whilst LC-MS/MS can be utilized as an alternative technology of unique advantages for 
simulations quantification of co-administrated mAbs or in the case of low recovery observed due to matrix 
interference with ELISA method. Although the routine usage of LC-MS is mainly hampered by the relatively 
time-consuming method development due to complex sample preparations, the availability of isotopically 
labeled proteins as ISs, immunocapture and enzyme digestion of LMs as well as limited sensitivity as 
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compared to a typical BLA, the highly selective LC-MS has been emerging as a viable alternative for 
qualitative and quantitative applications of LMs, which can achieve comparable detection sensitivity with 
ELISA for PK quantification of mAbs as demonstrated in a number of recent applications. Several multiple 
approaches have proposed to mitigate interference issues in LBA, including the use of LC-MS for bioanalysis 
of mAbs. However, it is desirable to deploy only one assay, rather than multiple assays, especially in later 
stages of clinical development. Due to the heterogeneous nature of ADCs and potential biotransformation, 
the hybrid technologies of best LBA and LC-MS/MS are imperative for molecular characterization, PK/TK 
bioanalysis including total antibody, total ADC, antibody-conjugated payload and unconjugated payload and 
immunogenicity evaluation as well as biotransformation and safety assessments of ADCs. 
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AAPS  American Association of Pharmaceutical Scientists 
ADA   anti-drug antibody 
ADC   Antibody-drug conjugates 
ADME   Absorption, distribution, metabolism and elimination 
API   Active pharmaceutical ingredient  
ATA   Anti-therapeutic antibodies 
AUC   Area under the curve 
BSA   Body surface area 
CDER  Center for drug evaluation and research 
CYP   Cytochrome P450 
DAR   Drug-antibody ratio, payload 
DDI   Drug-drug interaction 
ETAPC  The Emergent Technologies Action Program Committee 
ELISA  Enzyme-linked immunesorbent assay 
FIH   First-in-human 
hERG  Human ether-a-go-go related gene 
HIC   Hydrophobic interaction chromatography 
HNSTD  Highest non-severely toxic dose 
LBA   Ligand binding assay 
IgG   Immunoglobulin G 
IM   Intramuscular 
IND   Investigational new drug 
IS   Internal standard 
IV    Intravenous 
LC-MS  Liquid chromatography-mass spectrometry 
LC-MS/MS  Liquid chromatography with tandem mass spectrometry 
LMs   Large molecules 
mAb   Monoclonal antibody 
MMAE  Monomethyl auristatin E 
M&S  Modeling and simulation 
MTD   Maximum tolerated dose 
MW   Molecular weight 
PBPK   Physiologically-based pharmacokinetics 
PCC   Preclinical candidate 
PD    Pharmacodynamics 
PK    Pharmacokinetics 
PK/PD   Pharmacokinetics-pharmacodynamics 
PK/TK   Pharmacokinetics-toxicokinetics 
PTM   Post-translational modifications 
SC   Subcutaneous 
SMs   Small molecules 
TDC   ThioMab-drug conjugates 
T-DM1   Trastuzumab-emtansine 
TMB  3, 3', 5, 5' - Tetramethylbenzidine 
TMDD  Target-mediated drug disposition 
Vd   Volume of distribution 
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